The synthesis and biological evaluation of novel human A-FABP inhibitors based on the 6-(trifluoromethyl)pyrimidine-4(1H)-one scaffold is described. Two series of compounds, bearing either an amino or carbon substituent in the 2-position of the pyrimidine ring were investigated. Modification of substituents and chain length optimization led to novel compounds with low micromolar activity and good selectivity for human A-FABP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2004.06.058 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of Initial and Changes in Serum A-FABP Level With the Development and Improvement of Presarcopenia.
J Clin Endocrinol Metab
January 2025
Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai 200233, China.
Context: Several cross-sectional studies have reported the association between serum adipocyte fatty acid-binding protein (A-FABP) level and presarcopenia. However, data on the effects of serum A-FABP level and its changes over time on the development and improvement of presarcopenia are scarce.
Objective: This study aimed to explore the association of serum A-FABP level with the incidence and improvement of presarcopenia in a community-based cohort, and further investigated the association of changes in serum A-FABP level with the incidence and improvement of presarcopenia.
Development of a humanized anti-FABP4 monoclonal antibody for potential treatment of breast cancer.
Breast Cancer Res
July 2024
Department of Pathology, University of Iowa, 431 Newton Road, Iowa City, IA, 52242, USA.
Article Synopsis
- Breast cancer is a leading cancer among women globally, and obesity is a known risk factor whose molecular mechanisms are not fully understood.
- Recent studies identified a protein, A-FABP (FABP4), that links obesity-related changes in lipid metabolism to increased breast cancer risk, suggesting it could be a target for new treatments.
- Researchers developed humanized monoclonal antibodies, particularly a variant named 12G2, which effectively reduced FABP4 levels and inhibited tumor growth in mouse models, showing promise for breast cancer therapy.
Adipocyte fatty acid-binding protein (FABP4) as a potential biomarker for predicting metabolically driven low-grade and organ damage in thalassemia syndromes.
Ann Hematol
September 2024
Department of Internal Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Adipocyte fatty acid-binding protein (A-FABP; FABP4) plays a significant role in the pathogenesis and progression of metabolically driven low-grade inflammation and organ damage. This study aimed to evaluate the performance of circulating FABP4 as a predictive and diagnostic biomarker for thalassemia-associated cardiometabolic events. This case-control study enrolled 50 adults with β-thalassemia and 30 age-, sex-, and body mass index-matched controls.
View Article and Find Full Text PDFAdipose Tissue Dysfunction and the Role of Adipocyte-Derived Extracellular Vesicles in Obesity and Metabolic Syndrome.
J Endocr Soc
July 2024
Center for Translational Research in Endocrinology (CETREN-UC), Pontificia Universidad Católica de Chile, Santiago 8330074, Chile.
Obesity is a major public health issue that is associated with metabolic diseases including diabetes mellitus type 2 and metabolic syndrome. This pathology leads to detrimental cardiovascular health and secondary effects, such as lipotoxicity, inflammation, and oxidative stress. Recently, extracellular vesicles (EVs) have been highlighted as novel players participating in human physiology and pathophysiology.
View Article and Find Full Text PDFConcomitant decrease of E- and A-FABP expression predicts worse survival in urothelial bladder cancer patients.
Sci Rep
July 2024
Université Franche-Comté, SINERGIES - LabEx LipSTIC ANR-11-LABX-0021, 25030, Besançon, France.
Non-muscle invasive bladder cancers (NMIBC) pTa-pT1 are depicted by a high risk of recurrence and/or progression with an unpredictable clinical evolution. Our aim was to identify, from the original resection specimen, tumors that will progress to better manage patients. We previously showed that A-FABP (Adipocyte- Fatty Acid Binding Protein) loss predicted NMIBC progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!